|
Index
|
Baseline (mean ± SD)
|
Post-treatment (mean ± SD)
|
t/Z
|
P
|
|---|
|
Group A: 3 months of full-dose anti-TNFα (n = 10; n = 6 for anti-TNFα alone, n = 4 for combination)a
|
|
ASDAS
|
3.43 ± 1.55
|
1.66 ± 0.40
|
2.675
|
0.043
|
|
SPARCC
|
31.67 ± 18.64
|
14.50 ± 18.41
|
3.768
|
0.012
|
|
ESRb
|
52.00 ± 43.83
|
5.00 ± 5.55
|
–2.023
|
0.046
|
|
CRPb
|
36.58 ± 40.37
|
1.92 ± 1.09
|
–1.782
|
0.083
|
|
Group B: 4–6 months of anti-TNFα (n = 17; n = 4 for anti-TNFα alone, n = 13 for combination)c
|
|
ASDAS
|
2.46 ± 0.58
|
1.58 ± 0.69
|
4.920
|
<0.001
|
|
SPARCC
|
34.98 ± 18.93
|
18.54 ± 15.72
|
4.285
|
0.001
|
|
ESRb
|
27.77 ± 34.95
|
7.22 ± 12.31
|
–2.749
|
0.007
|
|
CRPb
|
16.34 ± 23.11
|
4.37 ± 17.87
|
–2.283
|
0.025
|
|
Group C: 9–12 months of anti-TNFα (n = 12; n = 6 for anti-TNFα alone, n = 6 for combination)d
|
|
ASDAS
|
2.91 ± 0.89
|
2.05 ± 1.21
|
2.517
|
0.042
|
|
SPARCC
|
38.24 ± 15.39
|
23.09 ± 15.65
|
2.527
|
0.038
|
|
ESRb
|
28.29 ± 27.77
|
12.43 ± 13.57
|
–1.498
|
0.128
|
|
CRPb
|
14.43 ± 11.65
|
10.81 ± 16.54
|
–1.529
|
0.134
|
-
aBaseline of clinical practices from patients in Group A: 85.7 % male; age, 23 ± 5.62; symptom duration, 2.6 ± 3.25; HLA-B27-positive, 85.7 %
-
bNot normally distributed, compared by paired rank test
-
cBaseline of clinical practices from patients in Group B: 85.7 % male; age, 23.3 ± 6.43; symptom duration, 3.15 ± 2.98; HLA-B27-positive, 100 %
-
dBaseline of clinical practices from patients in Group C: 80 % male; age, 21.3 ± 2.53; symptom duration, 3.97 ± 3.52; HLA-B27-positive, 90 %
-
ASDAS Ankylosing Spondylitis Disease Activity Indices, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, SD standard deviation, SPARCC Spondyloarthritis Research Consortium Canada, TNFα tumor necrosis factor alpha
